DiaMedica Accelerates Warrant Expiry Date
November 20 2017 - 2:12PM
DiaMedica (TSX-V:DMA) today on behalf of the board of directors
announces that in accordance with the terms of the warrant
indenture for warrants issued on April 18, 2017, the company has
provided written notice to holders of such warrants that the expiry
date has been accelerated to the close of business on December 11,
2017.
Under the terms of the April 18, 2017 warrant
certificates, if the volume-weighted average closing trading price
of the common shares on any recognized Canadian stock exchange
equals or exceeds USD$0.30 for a period of 10 consecutive trading
days, then, at the Company’s sole discretion and upon the Company
sending the holder written notice of such Accelerated Exercise Date
(the “Notice”) and issuing a news release announcing such
Accelerated Exercise Date (the “News Release”), the day that is 21
days following the later of: (i) the date on which such Notice is
sent to the holder; and (ii) the date on which the News Release is
issued. If all of the 2,631,579 outstanding warrants subject to
this acceleration are exercised, DiaMedica will receive additional
proceeds of USD$605,263. Any warrants not exercised prior to the
accelerated expiry date and time will expire without any further
action being taken.
About DiaMedica Therapeutics
Inc.
DiaMedica Therapeutics is a clinical stage
biopharmaceutical company focused on developing novel treatments
for neurological and kidney diseases. DiaMedica's shares are listed
on the TSX Venture Exchange under the trading symbol "DMA" and on
the OTCQB under the trading symbol "DMCAF". For more information,
please visit www.diamedica.com. Follow us on social media –
Twitter, LinkedIn.
Contact:
Paul Papi Vice President of Business Development
DiaMedica Therapeutics Inc. Phone: (617) 899-5941
info@diamedica.com
Tweet this!
FORWARD-LOOKING
STATEMENTS
The statements made in this press release that
are not historical facts contain forward-looking information that
involves risk and uncertainties. All statements, other than
statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such
statements are based on management's exercise of business judgment
as well as assumptions made by and information currently available
to management. When used in this document, the words "may", "will",
"anticipate", "believe", "estimate", "expect", "intend" and words
of similar import, are intended to identify any forward-looking
statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view
of future events and are subject to certain risks and uncertainties
as contained in the DiaMedica's filings with the Canadian
securities regulators, all of which are available on SEDAR
(www.sedar.com). Should one or
more of these risks or uncertainties materialize, or should
underlying assumptions prove incorrect, actual results could differ
materially from those anticipated in these forward-looking
statements. DiaMedica undertakes no obligation, and does not
intend, to update, revise or otherwise publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence
of any unanticipated events, unless required by law. Although
management believes that expectations are based on reasonable
assumptions, no assurance can be given that these expectations will
materialize.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of the contents of this press release.
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024
DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024